Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Boehringer Ingelheim
Johnson and Johnson
Merck
UBS
Teva
Deloitte
Queensland Health
Julphar

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,982,283

« Back to Dashboard

Which drugs does patent 6,982,283 protect, and when does it expire?

Patent 6,982,283 protects AMITIZA and is included in one NDA.

This patent has twenty patent family members in eighteen countries.
Summary for Patent: 6,982,283
Title:Method for treating drug-induced constipation
Abstract: Provided is a method for treating drug-induced constipation comprising a step of administering an effective amount of a 15-keto-prostaglaindin compound to a subject suffering from drug-induced constipation or a subject having a strong possibility of suffering from it. According to the present invention, a strong antagonistic action against drug-induced constipation can be obtained without substantially losing the main effect of the drug.
Inventor(s): Ueno; Ryuji (Montgomery, MD)
Assignee: Sucampo AG (Zug, CH)
Application Number:10/135,397
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,982,283
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,982,283

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-001 Jan 31, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,982,283

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 035237 ➤ Try a Free Trial
Argentina 100696 ➤ Try a Free Trial
Austria 355067 ➤ Try a Free Trial
Australia 2002251554 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Cipla
Daiichi Sankyo
Deloitte
Moodys
AstraZeneca
Harvard Business School
Federal Trade Commission
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.